Skip to main content

Security report for biogen.no

Biogen Norway AS · Healthcare · Norway

Low risk. 2 critical or high findings in Email security and SSL/TLS.

Security score

81/100

Risk levelLow

0–100, higher is better. How it is calculated

Biogen Norway AS operates as a leading global biotechnology company specializing in neurology, neuropsychiatry, specialized immunology, and rare diseases. The company focuses on research, development, and innovation to improve patient lives and contribute to a healthier, sustainable world. The website targets healthcare professionals, patients, and stakeholders primarily in Norway, providing comprehensive information about therapies, corporate responsibility, and career opportunities. Technically, the website is built on Adobe Experience Manager CMS, leveraging modern JavaScript libraries such as jQuery and Adobe Helix RUM for performance monitoring. It employs Google Analytics and Google Tag Manager for analytics and tracking, alongside Cookiebot for cookie consent management. The site is mobile-optimized with good SEO and accessibility features, though some accessibility improvements are recommended. From a security perspective, the site enforces HTTPS and uses secure cookies with httpOnly flags. It implements a detailed cookie consent mechanism compliant with GDPR. However, it lacks explicit security headers and published security policies or incident response contacts, which are recommended for enhanced trust and compliance. Overall, the website presents a professional, trustworthy digital presence with strong privacy compliance and good technical implementation. The absence of WHOIS data is a limitation but does not detract significantly from the site's legitimacy given the quality of content and security posture.

Scanned

NIS2 and GDPR posture

GDPR outside view
83/ 100 · Low
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

2 findings rated critical or high. Fix these first.

  1. Email security

    SPF, DKIM and DMARC stop others sending email that looks like it comes from your domain, a common route to phishing and invoice fraud.

    • Critical

      No email authentication configured

      Domain is vulnerable to email spoofing

      What to do: Implement SPF, DKIM, and DMARC immediately

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching biogen.no

This scan found 17 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. See sample alerts.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
72
Security headers
95
Email security
60
DNS health
75
Network security
100
GDPR outside view
83
Average
81

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Breach exposure

Leaked credentials and lookalike domains from OffSeq Breach. The counts are free; the detailed lists are paid add-ons.

Dark web exposure

Add-on

Leaked records that mention biogen.no, from OffSeq Breach.

No leaked records found

Breach holds no records for biogen.no right now. New leaks arrive continuously, so monitoring on Breach alerts you if that changes.

Monitor on Breach (opens in a new tab)

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Biogen Norway AS holds a strong market position as a global biotechnology leader focusing on neurological and rare diseases. The company’s business model centers on innovative drug development and patient-centric services. Its digital presence supports brand awareness, stakeholder engagement, and recruitment. The company maintains a broad partnership ecosystem evident from its global domain network. Growth indicators include active content updates, comprehensive privacy compliance, and multi-channel social media engagement. The website’s structure and content reflect a mature organization with clear strategic focus on healthcare innovation and corporate responsibility.

Security posture

The website demonstrates a mature security posture with mandatory HTTPS, secure cookie practices, and GDPR-compliant cookie consent. However, it lacks visible security headers such as Content-Security-Policy and X-Frame-Options, which are best practices to mitigate common web attacks. No incident response or security contact information is published, limiting transparency in case of security events. The use of third-party scripts like Google Analytics and Cookiebot is managed with user consent, reducing privacy risks. Overall, the security maturity is good but can be improved by publishing security policies and implementing additional HTTP security headers.

Recommendations

  1. Implement and enforce HTTP security headers including Content-Security-Policy, X-Frame-Options, and X-Content-Type-Options to enhance protection against common web vulnerabilities.
  2. Publish a dedicated security policy and incident response page with clear contact channels to improve transparency and trust.
  3. Regularly audit and update third-party scripts and libraries to mitigate potential vulnerabilities.
  4. Enhance accessibility features to meet higher compliance standards and improve user experience for all visitors.
  5. Consider resolving WHOIS data visibility issues to improve domain transparency and trustworthiness.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Biogen Norway AS
Description
Biogen er et ledende globalt bioteknologiselskap som er pionérer innen vitenskap og fremmer innovasjon innen komplekse og alvorlige sykdommer. Biogen utvikler en pipeline med potensielle behandlinger innen nevrologi, nevropsykiatri, spesialisert immunologi og sjeldne sykdommer. Vi jobber også målrettet for å bidra med vitenskap som fører til en sunnere, mer bærekraftig og rettferdig verden.
Key services
Research and development of therapies, Patient support and education, Information dissemination on neurological and rare diseases
Content quality
good
Branding
consistent

Technology

Stack
jQuery 3.6.4, Adobe Helix RUM, Cookiebot, Google Tag Manager, Google Analytics
Frameworks
Adobe Experience Manager (AEM)
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • Cookie consent banner with granular controls
  • Use of httpOnly cookies for security
  • Load balancing cookies for performance

Analytics and tracking

Services
Google Analytics
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Cookiebot session tracker
Marketing tools
Cookiebot
Transparency
good

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is fully accessible with rich content in Norwegian language
  2. Strong focus on healthcare and biotechnology sector
  3. Comprehensive cookie consent and privacy mechanisms implemented
  4. No direct contact emails or phone numbers found in visible content; contact via form page
  5. No explicit security policy or incident response information published
  6. Use of modern web technologies and Adobe Experience Manager CMS
  7. Social media presence on major platforms with official company pages
  8. No suspicious or malicious content detected
  9. WHOIS data unavailable, which reduces transparency but does not directly indicate fraud
Technical notes

Notes

The website is built on Adobe Experience Manager CMS, indicating a robust enterprise-grade content management platform. It uses modern JavaScript libraries including jQuery 3.6.4 and Adobe Helix RUM for real user monitoring. Google Tag Manager and Google Analytics are integrated for analytics and marketing insights. Cookiebot manages cookie consent with granular user controls, supporting GDPR compliance. The site is mobile responsive with good SEO metadata and Open Graph tags for social sharing. Performance is moderate, with potential improvements in loading speed and accessibility. No hosting provider details were identified from the content. Overall, the technical infrastructure supports a professional and compliant digital presence.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with biogen.no. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review biogen.no.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.